STOCK TITAN

PDS Biotech to Announce Third Quarter Financial Results on November 14, 2024 at 8:30 a.m. Eastern Time

Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags

PDS Biotechnology (Nasdaq: PDSB), a late-stage immunotherapy company focused on cancer treatment and infectious disease vaccines, has scheduled its Q3 2024 financial results conference call for November 14, 2024, at 8:30 AM ET. The company will present financial results for the quarter ended September 30, 2024, along with a clinical program update. Participants can join via phone (1-877-704-4453 or 1-201-389-0920) or through the webcast registration link.

PDS Biotechnology (Nasdaq: PDSB), una compagnia di immunoterapia in fase avanzata focalizzata sul trattamento del cancro e sui vaccini per le malattie infettive, ha programmato la sua call per i risultati finanziari del Q3 2024 per il 14 novembre 2024, alle 8:30 AM ET. L'azienda presenterà i risultati finanziari per il trimestre conclusosi il 30 settembre 2024, insieme a un aggiornamento sui programmi clinici. I partecipanti possono unirsi tramite telefono (1-877-704-4453 o 1-201-389-0920) o attraverso il link di registrazione del webcast.

PDS Biotechnology (Nasdaq: PDSB), una empresa de inmunoterapia en etapa avanzada centrada en el tratamiento del cáncer y las vacunas para enfermedades infecciosas, ha programado su conferencia de resultados financieros del Q3 2024 para el 14 de noviembre de 2024, a las 8:30 AM ET. La compañía presentará los resultados financieros del trimestre que terminó el 30 de septiembre de 2024, junto con una actualización del programa clínico. Los participantes pueden unirse por teléfono (1-877-704-4453 o 1-201-389-0920) o a través del enlace de registro del webcast.

PDS Biotechnology (Nasdaq: PDSB), 암 치료 및 전염병 백신에 초점을 맞춘 후기 단계 면역 요법 회사가 2024년 3분기 재무 결과 콘퍼런스 콜을 2024년 11월 14일 오전 8시 30분 ET에 개최할 예정입니다. 이 회사는 2024년 9월 30일 종료된 분기 재무 결과와 임상 프로그램 업데이트를 발표할 것입니다. 참가자는 전화(1-877-704-4453 또는 1-201-389-0920) 또는 웹캐스트 등록 링크를 통해 참여할 수 있습니다.

PDS Biotechnology (Nasdaq: PDSB), une société d'immunothérapie en phase avancée axée sur le traitement du cancer et des vaccins contre les maladies infectieuses, a programmé sa conférence téléphonique sur les résultats financiers du T3 2024 pour le 14 novembre 2024 à 8h30 ET. L'entreprise présentera les résultats financiers pour le trimestre clos le 30 septembre 2024, ainsi qu'une mise à jour sur le programme clinique. Les participants peuvent se joindre par téléphone (1-877-704-4453 ou 1-201-389-0920) ou via le lien d'inscription au webinaire.

PDS Biotechnology (Nasdaq: PDSB), ein fortgeschrittenes Immuntherapieunternehmen, das sich auf die Krebsbehandlung und Impfstoffe gegen infektiöse Krankheiten konzentriert, hat seine Konferenzschaltung für die Finanzzahlen des Q3 2024 für den 14. November 2024 um 8:30 Uhr ET angesetzt. Das Unternehmen wird die finanziellen Ergebnisse für das am 30. September 2024 endende Quartal sowie ein Update zum klinischen Programm präsentieren. Teilnehmer können telefonisch (1-877-704-4453 oder 1-201-389-0920) oder über den Registrierungslink für die Webkonferenz teilnehmen.

Positive
  • None.
Negative
  • None.

PRINCETON, N.J., Nov. 06, 2024 (GLOBE NEWSWIRE) -- PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines, today announced that the Company will host a conference call to report financial results for the quarter ended September 30, 2024, and provide a clinical program update on Thursday, November 14, 2024, at 8:30 a.m. Eastern Time.

Conference Call Details

Date: November 14, 2024
Time: 8:30 a.m. Eastern Time
Dial-in: 1-877-704-4453 or 1-201-389-0920
Webcast Registration: Click Here
Call MeTM Registration: Click Here (Available 15 minutes prior to call)

About PDS Biotechnology
PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and the development of infectious disease vaccines. The Company plans to initiate a pivotal clinical trial in 2024 to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor. We believe that proof-of-concept long-term data have shown positive survival results and tumor shrinkage with these combinations and indicate favorable tolerability.

We believe that the novel investigational mechanisms of action of Versamune® HPV and the combination of Versamune® HPV and PDS01ADC have resulted in compelling results with potential to successfully disrupt a tumor’s internal defenses, while also generating potent, targeted killer T-cells to attack the tumor. We also believe that data from more than 350 patients, as well as ongoing clinical trials across multiple tumor types and standard treatment regimens, have validated the potential for both platforms and point to potential broad utility.

For more information, please visit www.pdsbiotech.com.

Forward Looking Statements
This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for Versamune® HPV, PDS01ADC, and other Versamune® and Infectimune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning Versamune® HPV, PDS01ADC and other Versamune® and Infectimune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  

Versamune® and Infectimune® are registered trademarks of PDS Biotechnology Corporation.

Investor Contact:
Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: mmoyer@lifesciadvisors.com

Media Contact:
Janine McCargo
6 Degrees
Phone +1 (646) 528-4034
Email: jmccargo@6degreespr.com


FAQ

When will PDS Biotech (PDSB) report Q3 2024 earnings?

PDS Biotech (PDSB) will report its Q3 2024 earnings on November 14, 2024, at 8:30 AM Eastern Time.

How can investors join PDS Biotech's (PDSB) Q3 2024 earnings call?

Investors can join PDSB's Q3 2024 earnings call by dialing 1-877-704-4453 (US) or 1-201-389-0920 (International), or through the webcast registration link provided by the company.

What will PDS Biotech (PDSB) discuss in their November 14 conference call?

PDS Biotech will discuss their Q3 2024 financial results for the quarter ended September 30, 2024, and provide updates on their clinical programs.

PDS Biotechnology Corporation

NASDAQ:PDSB

PDSB Rankings

PDSB Latest News

PDSB Stock Data

78.93M
36.02M
3.99%
12.36%
12.14%
Biotechnology
Pharmaceutical Preparations
Link
United States of America
PRINCETON